LY 296242
Latest Information Update: 02 Sep 1998
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 02 Sep 1998 No-Development-Reported for HIV-1 infections in USA (Unknown route)
- 08 May 1995 New profile
- 08 May 1995 Preclinical development for HIV-1 infections in USA (Unknown route)